NVCR - NovoCure GAAP EPS of -$0.54 misses by $0.04 revenue of $126.05M beats by $1.8M
2023-07-27 07:11:47 ET
- NovoCure press release ( NASDAQ: NVCR ): Q2 GAAP EPS of -$0.54 misses by $0.04 .
- Revenue of $126.05M (-10.5% Y/Y) beats by $1.8M .
- 3,571 active patients on therapy as of June 30, 2023
- Phase 3 LUNAR trial in non-small cell lung cancer met primary and key secondary survival endpoints, the first of four phase 3 trials to readout by year-end 2024
- Interim analysis for fully enrolled phase 3 PANOVA-3 trial in pancreatic cancer concluded with recommendation to proceed to final analysis.
For further details see:
NovoCure GAAP EPS of -$0.54 misses by $0.04, revenue of $126.05M beats by $1.8M